updat model diagnost servic compani follow earn
sec file
note provid updat model diagnost servic coverag list summari
estim chang updat stock thought
summari vast major small lab posit result second quarter
particularli term volum growth lab proprietari test also saw
benefit price due implement pama gener valuat
space re-rat see valuat chart end note given stabl
reimburs environ favor regulatori environ volum growth
larger lab less favor result quest miss volum labcorp report
sequenti declin book-to-bil cro busi
small-cap idea like higher end valuat rang
see potenti inflect base grow pharma busi potenti fda approv
comprehens genom profil assay lung franchis give second
third leg stool increasingli intrigu expans area
genom space although multipl perspect gap stock
other space meaning narrow mid-/larg cap see quest diagnost
well posit unitedhealthcar contract chang myriad
interest catalyst-driven name next six month despit run-up
laboratori corpor america hold
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
genom health second quarter compani report top-lin growth constant-curr basi driven
volum growth reimburs tailwind posit impact pama better privat payer coverag improv
collect compani benefit public tailorx result start june evidenc sequenti
volum growth invas breast cancer test busi month outsid unit state genom health continu
expect posit reimburs decis unit kingdom germani compani plan launch kit-
base oncotyp dx test breast cancer germani franc sometim earli despit strong perform
first half year manag elect maintain previous commun full-year guidanc includ expect
revenu million million growth although manag expect revenu fall high
end provid rang result tailorx studi provid momentum near term hold
see evid compani abl capit current momentum drive long-term growth thu
reaffirm market perform rate
post anoth quarter impress volum growth although revenu per billabl test came slightli
expect adjust impact million one-tim payment medicar previous perform del/dup
analysi quarter compani access approxim test repres growth prior year
continu see room upsid volum estim steadi growth intern volum record order new
account increas number account start order oncolog reproduct health test
also intrigu compani expans new area carrier screen prenat genet somat test via
relationship kew believ compani becom compel stori given thesi genom
market central key player maintain market perform rate continu look
clariti improv revenu per billabl test compani cash burn trajectori
labcorp base ttm book-to-bil ratio provid quarter estim compani report book-to-bil ratio
approxim time second quarter deterior book-to-bil ideal opinion reaction
subsequ sell-off compani stock overdon compani report sever quarter industry-lead
book-to-bil metric develop sever signific relationship quarter benefit compani move
forward outsid covanc result diagnost segment encourag especi consid lower-than-expect
organ growth report number move part may make futur estim messi
next quarter includ divestitur food solut busi serv optic lower report revenu
per requisit impact pama dynam unitedhealthcar aet contract
chang howev high level believ compani abl build scale diversifi cro busi leverag
labcorp broad patient access lead revenu synergi longer term also diagnost side busi
continu believ earli inning secular shift market share lower-cost larger lab due medicar
reimburs pressur increas effort part privat payer reduc lab spend strateg way maintain
myriad hereditari cancer busi remain stabl view riskscor recent bracanalysi cdx
approv potenti upsid catalyst compani continu make progress diversifi away legaci
busi number reimburs catalyst could provid materi upsid top bottom line
beyond significantli guidanc assum known reimburs coverag genesight public
guid impact optum studi posit compani increas commerci coverag compani complet
acquisit counsyl end juli guidanc assum contribut million top line neutral
earn opinion estim overli conserv previous publish scenario analysi
estim roughli upsid ep guidanc acquisit given compani well
posit drive improv reimburs coverag commerci coverag genesight signific catalyst
base fact consider room upsid estim impact recent counsyl acquisit
maintain outperform rate
neogenom compani report midteen volum growth quarter includ growth across test type molecular
test pharma continu highlight compani announc becam in-network
provid effect august addit strong underli busi overal stable/posit reimburs
environ continu believ compani inflect point given grow pharma busi focu
differenti via fda approv pharma compani report addit million new contract quarter
backlog greater million last year recent agreement facilit
compani expans singapor shanghai manag target million revenu run-rat
allianc end fda approv long-term catalyst view one compani
scale technic knowledg necessari benefit recent medicar ncd foundationon cdx reiter
outperform rate
second-quart result slightli expect unitedhealthcar contract
substanti volum tailwind add million live compani network number potenti benefit
unitedhealthcare/aetna contract renew addit increas volum includ value-bas price
potenti market share gain region lab manag provid guidanc impact renew
previous estim contract chang increas adjust ep perhap
importantli continu believ quest benefit hospit need lower cost rais capit result
implement pama view earli phase shift market share hospit lab independ lab
result reaffirm outperform rate
report second-quart result solidli beat expect afirma franchis continu gain traction
compani begin benefit abil leverag data gener afirma xpression atla launch may
second quarter compani recogn million revenu recent announc agreement loxo
oncolog loxo outperform base data gener previous mention afirma xpression atla
remain encourag uptak compani percepta test highlight veracyt develop lung franchis
percepta test perform quarter million percepta revenu compani way build legitim
second product franchis meet goal exit run-rat percepta test per quarter also
within lung build data suggest compani envisia test idiopath pulmonari fibrosi ipf track obtain
medicar coverag collect compani three product afirma percepta envisia address market expect
grow billion billion encourag scientif innov see
potenti meaning upsid compani emerg lung franchis reiter outperform rate
genom health report strong second quarter breast cancer revenu ahead estim compani maintain full
year outlook although manag indic compani like report toward higher end
guidanc rang rais revenu estim breast cancer franchis posit result tailorx studi
drive addit volum second half year manag also expect pickup intern price favor
reimburs decis come unit kingdom germani later year
forecast total revenu million versu prior million adjust ep versu prior
within model breast cancer revenu million versu prior million prostat cancer revenu
million versu prior million prostat cancer forecast includ revenu oncotyp dx nucleu detect
test manag expect provid signific fourth-quart contribut model gross margin versu prior
oper margin versu prior compani plan increas spend strateg import
program second half year third quarter model revenu million adjust ep
previous detail recap model chang anoth impress quarter includ strong volum growth increas
revenu per test updat model base manag commentari result first two quarter
total expect revenu million growth versu prior estim million growth
consensu million expect total access growth versu prior estim
growth move past expect revenu million versu prior estim million
consensu assum revenu million term volum expect compani access roughli
test versu prior estim
laboratori corpor america lh
updat labcorp model second-quart result manag guidanc sever factor drive
compani guidanc chang includ lower expect foreign currenc benefit improv outlook cro busi
divestitur covanc food solut busi overal project full year revenu billion versu prior
billion updat gross margin oper margin virtual unchang forecast adjust ep
versu prior adjust ep estim estim reflect estim
impact covanc food solut divestitur third quarter estim overal revenu billion adjust ep
expect labcorp diagnost revenu growth remain lumpi next quarter due impact pama prior-
year hurrican unitedhealthcare/aetna contract chang upcom divestitur covanc food solut busi
first three factor alreadi model forecast howev fine-tun assumpt model
increment chang divestitur covanc food solut transact expect close third quarter
busi contribut million diagnost revenu report revenu per requisit significantli higher
overal diagnost segment margin roughli line segment
lower estim diagnost full-year volum growth versu prior model revenu
per requisit declin basi point versu prior increas chang volum forecast driven
divestitur chang revenu per requisit forecast driven trend difficult second quarter compani
report declin versu expect growth expect impact divest busi overal
expect compani report full-year diagnost revenu billion versu prior billion covanc segment
forecast revenu billion versu prior billion revenu growth versu prior
updat myriad model compani releas fiscal result outlin review note compani
sever move part forecast particularli hereditari cancer busi recent close counsyl acquisit
estim overal fiscal revenu million adjust ep estim impli organ revenu growth
adjust fiscal revenu base plan german clinic dispos
myriad expect hereditari cancer franchis maintain stabl price grow volum off-set variou factor unrel
core busi growth first account standard affect report revenu fiscal doubt revenu
directli deduct revenu line manag estim off-set million fiscal mainli
affect hereditari cancer revenu assum remain similar level fiscal second myriad plan sell
german clinic end first half fiscal year clinic gener million revenu six month fiscal
assum fiscal contribut would remain consist clinic sold summari
forecast hereditari busi declin report term fiscal composit nomin underli growth
off-set impact german clinic sale
myriad also complet counsyl acquisit juli manag indic counsyl would merg myriad
exist prevent care busi new busi unit name myriad women health current forecast counsyl busi
model separ product extrapol compani comment model million acquisit financ
million fresh equiti million debt myriad credit facil remain market
secur cash hand also assum myriad abl pay addit debt end fiscal
manag guid toward roughli million counsyl revenu fiscal month ownership model
new product myriad guid double-digit growth assum addit reimburs beyond
compani alreadi secur revis estim stay line aspect guidanc addit recommend
coverag decis would serv upsid guidanc estim forecast fiscal revenu million
genesight versu prior million million vectra versu prior million million prolari versu
prior million million endopredict versu prior million model million revenu
pharmaceut clinic servic versu prior million
counsyl gross margin well myriad exist rang estim margin dilut lower
overal gross margin fiscal fiscal fiscal gross margin would adjust
oper expens line also affect sever factor integration-rel salesforc disrupt initi
month fiscal year on-going gain elev impact doubt revenu shift oper
expens revenu off-set myriad decis exclud stock-bas compens adjust earn model
adjust oper margin fiscal compar fiscal fiscal oper margin
adjust stock-bas compens would
first quarter fiscal manag expect see typic summer weak affect test volum quarter
also includ first two month counsyl revenu believ would margin disrupt earli integr
effort estim fiscal first-quart revenu million adjust ep
previous detail review highlight anoth encourag quarter model chang primarili reflect prefer
stock redempt updat neogenom model reflect second-quart result manag commentari
compani outlook remaind increas estim third-quart revenu million
repres growth report basi unadjust impact versu previou estim million
growth report basi estim total revenu million growth adjust basi versu
previou estim million growth adjust basi forecast revenu million versu
previou estim million chang primarili reflect increas expect averag revenu per test
off-set slightli conserv estim clinic test volum growth addit given signific pharma backlog
end second quarter increas estim pharma servic revenu growth
manag reiter guidanc adjust ebitda rang million million decreas guidanc
adjust dilut ep compar previou guidanc base result quarter
expect adjust ebitda million growth adjust basi adjust ebitda million
previous estim adjust ebitda million growth adjust basi adjust ebitda
million overal left margin rel flat higher expect gross margin off-set increas estim
oper expens driven compani current on-going invest bottom line expect adjust ep
adjust ep versu prior estim adjust ep adjust ep
chang larg driven increas interest expens result compani new long-term debt
follow second-quart earn updat model reflect guidanc chang addit inform provid
call compani narrow guidanc rang lower midpoint estim revenu ep report
lower-than-expect organ revenu growth second quarter manag highlight headwind volum declin
hepat genotyp payer polici chang prescript drug monitor reimburs denial vitamin test
driver top-lin miss second quarter compani believ hepat genotyp may continu
declin futur quarter prescript drug monitor vitamin dynam persist specif expect mark
improv organ growth second half easier prior-year comp perform second half
includ impact hurrican unit state possibl earli volum gain unitedhealthcar contract
inclus compani also clarifi spend invest relat unitedhealthcar contract includ guidanc
substanti part spend includ cost-of-sal line rather oper expens line
updat model assum overal revenu growth versu prior yield full year revenu
billion versu prior billion estim full year adjust ep versu prior revenu growth
driver includ diagnost organ revenu growth versu prior believ price pressur observ
second quarter may continu second half year offset volum gain expect growth organ
volum versu prior declin averag organ revenu per requisit full year versu prior
increas estim inorgan revenu growth versu prior base manag commentari invest
unitedhealthcar contract margin trend first half year shift invest expenditur
oper expens line cost-of-good line lower gross margin estim versu prior
leav oper margin estim nearli unchang versu prior third quarter expect
compani report revenu billion adjust ep
previous detail anoth quarter beat-and-rais continu traction second product lung cancer
percepta updat model reflect second-quart result manag commentari
compani outlook remaind increas estim third-quart revenu million
growth versu previou estim million growth estim revenu million growth
versu previou estim million growth chang primarili reflect increas expect averag
accrual per test well million biopharma servic revenu second half year forecast revenu
million versu previou estim million
manag reiter previous commun guidanc flat gross margin second half year
million million per quarter sales-and-market expens combin cost within rang million
million howev state manag narrow annual cash burn guidanc million million
estim cash burn million versu previou estim million driven primarili better-than-
expect result second quarter
thousand except share per share amount
product sold
thousand except share per share amount
revenu
accret redeem prefer
net incom attribut common stockhold
margin analysi recogn
research develop
sell market
gener administr
research develop
sell market
gener administr
laboratori corpor america hold
million except per share data
revenu excl
ebitda incl incom equiti invest
incom equiti invest
net incom attribut lh excl nonrec intang amort
intang amort net tax
non-recurring item net tax
bad debt revenu
thousand except per share data
total revenu
net incom excl nonrecur continu oper
non-recurring item net tax
ep continu oper excl non-recurring
ep continu oper
ep continu oper fully-tax
thousand except per share data
good sold
ebit loss oper
adjust gaap net incom
gaap net incom avail common sharehold
gaap net incom prefer share
percent revenu
tax ebt
incom loss oper
million except per share data
revenu
ebitda includ incom equiti invest
equiti earn jv post-tax incom
minor share incom
earn alloc particip securiti
adjust net incom cont op
amort net tax
adjust net incom cont op ex amort
non recur item net tax
incom loss discontinu oper net tax
equiti earn jv
minor share incom
ep cont op excl non recur item amort
thousand except share per share amount
servic
research develop
research develop
research develop
william blair affili manag co-manag public offer equiti secur invita corpor inc
inc within prior month
william blair affili benefici control either directli manag account equiti secur
inc end month end day date herein
william blair affili market maker secur genom health inc invita corpor laboratori corpor america
hold inc inc quest diagnost incorpor inc
william blair affili expect receiv intend seek compens invest bank servic genom health inc
invita corpor laboratori corpor america hold inc inc incorpor
inc affili within next three month
william blair affili receiv compens invest bank servic non-investment-bank servic
corpor inc inc within last month invita corpor inc inc
within last month invest bank client william blair compani and/or one affili
offic employe william blair affili research analyst may financi interest secur
genom health inc invita corpor laboratori corpor america hold inc inc quest
diagnost incorpor inc
report avail electron form regist user via doc http //williamblairlibrari bluematrix com
pleas contact us consult williamblair com/research-and-insights/equity-research/coverag aspx disclosur
